STOCKHOLM, Sweden, May 2, 2022. Karolinska Development AB announces that its portfolio company Biosergen is preparing a Phase 2 clinical trial of the company’s lead compound BSG005, targeting. | May 2, 2022
Investegate announcements from Karolinska Development AB (pub, Karolinska Development’s portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients
STOCKHOLM, Sweden, May 2, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen is preparing a Phase 2 clinical trial of the company's lead compound BSG005
STOCKHOLM, SWEDEN, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has enrolled all patients in the clinical study TOP FUSION, which
STOCKHOLM, Sweden, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic's IPO offering was fully subscribed. Promimic is now provided with